THE COURSE OF PREGNANCY IN WOMEN WITH METABOLIC SYNDROME IN VIEW OF PATHOGENETIC ROLE OF THROMBOPHILIA
Abstract
Metabolic syndrome is widespread among women of reproductive age. Metabolic syndrome is associated with at higher risk of developing various obstetric complications. The endothelial dysfunction, proinflammatory status and thrombophilic status may play an important role in impaired invasion cytotrophoblast and impaired placental development
in women with metabolic syndrome.
in women with metabolic syndrome.
About the Authors
E. B. Perederyaeva
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
T. B. Pshenichnikova
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. V. Donina
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. D. Makatsariya
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
D. L. Kapanadze
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Belocerkovceva L.D., Kovalenko L.V., Korneeva E.V. i dr. Osobennosti metabolicheskogo sindroma u zhenshhin v razlichnye periody zhizni: patogenez, klinika, diagnostika, lechenie. M. 2010; 73 s.
2. Berihanova R.R. Osobennosti techenija beremennosti, rodov, poslerodovogo perioda u pacientok s metabolicheskim sindromom. Dis. … kand. med. nauk. Volgograd. 2009; 166 s.
3. Bicadze V.O. Patogenez, principy diagnostiki i profilaktiki oslozhnenij beremennosti, obuslovlennyh trombofiliej. Diss. …dokt. med. nauk. M., 2004.
4. Borovkova E.I. Vedenie beremennosti u pacientov s izbytochnym vesom i ozhireniem. Materialy obrazovatel'nogo seminara «Reproduktivnoe zdorov'e zhenshhin vne i vo vremja beremennosti. M. 2010; 23-27.
5. Borovkova E.I. Taktika vedenija beremennyh s ozhireniem i metabolicheskim sindromom. Dis. … dokt. med. nauk. M. 2013; 48 s.
6. Burumkulova F.F., Petruhin V.A., Kovalenko T.S., Titova T.V., Golovchenko M.A. Gestacionnyj saharnyj diabet –mezhdisciplinarnaja problema. Materialy X jubilejnogo Vseross. nauchnogo foruma «Mat' i ditja». M. 2009; 30-31.
7. Gadaeva Z.K. Chastota i spektr polimorfizmov provospalitel'nyh citokinov i trombofilii u beremennyh s metabolicheskim sindromom i gestozom. Materialy X jubilejnogo Vserossijskogo nauchnogo foruma «Mat' i Ditja». M. 2009; 42 s.
8. Gorohova L.G. Dinamika obmena uglevodov i lipidov v sisteme mat' – plod – novorozhdennyj pri ozhirenii u zhenshhin. Avtoref. dis. … kand. biol. nauk. Irkutsk. 1995; 19 s.
9. Dedov I.I., Mel'nichenko G.A. Ozhirenie. Jetiologija, patogenez, klinicheskie aspekty. M. 2004; 216-232.
10. Dmitriev A.N. Ozhirenie i metabolicheskij sindrom. Ekaterinburg. 2001.
11. Erchenko E.N. Patofiziologicheskie osobennosti uglevodnogo i lipidnogo obmenov i sostojanie novorozhdennyh u beremennyh s izbytochnoj massoj tela i ozhireniem. Avtoref. dis. ... kand. med. nauk. M. 2009; 28 s.
12. Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. M. 2011; 220 s.
13. Kuzin A.I., Lengin Ju.A. Metabolicheskij sindrom: klinicheskie i populjacionnye aspekty. Cheljabinsk. 2001.
14. Kuz'mina-Kruteckaja S.R., Repina M.A. Metabolicheskij sindrom u zhenshhin. Spb. 2011; 76 s.
15. Makarov I.O., Shilov E.M. Petunina N.A i dr. Techenie beremennosti, rodov i poslerodovogo perioda u zhenshhin s metabolicheskim sindromom. Rossijskij vestnik akusheraginekologa. 2012; 3: 36-41.
16. Makacarija A.D., Bicadze V.O. Trombofilii i protivotromboticheskaja terapija v akusherskoj praktike. M. 2003; 904 s.
17. Makolkin V.I. Metabolicheskij sindrom. M. 2010; 144 s.
18. Mamedov M.N. Komponenty metabolicheskogo sindroma u bol'nyh s arterial'noj gipertoniej. Diss. … kand. med. nauk. M. 1997; 100 s.
19. Metabolicheskij sindrom i trombofilija v akusherstve i ginekologii / A.D. Makacarija, E.B. Pshenichnikova, T.B. Pshenichnikova, V.O. Bicadze. M. 2006; 480 s.
20. Mochalov A.A., Sokolov E.I.,. Manuhin I.B. Narushenija v sisteme gemostaza i ego korrekcija u beremennyh s metabolicheskim sindromom. Lechashhij vrach. 2011; 3: 43-47.
21. Mychka V.B., Chazova I.E. Metabolicheskij sindrom: diagnostika i differencirovannyj podhod k lecheniju. Medicina. Kachestvo zhizni. 2005. 3 (10): 28-33.
22. Ozhirenie. Rukovodstvo dlja vrachej. Pod redakciej N.A. Beljakova, V.I. Mazurova. SPb. 2003; 96-119, 219-234.
23. Perederjaeva E.B. Osnovnye principy vedenija beremennosti i bezopasnogo rodorazreshenija u zhenshhin s metabolicheskim sindromom. Dis. … kand. med. nauk. M. 2006; 149 s.
24. Sarkisova A.V. Techenie beremennosti i rodov u zhenshhin s metabolicheskim sindromom. Dis. … kand. med. nauk. M. 2004; 85 s.
25. Semihnenko I.N. Klinicheskoe znachenie vitaminnogo disbalansa u bol'nyh s metabolicheskim sindromom. Avtoreferat diss. …kand. med. nauk. Tjumen'. 2003; 30 s.
26. AACE Position Statement on Insulin Resistance Syndrome. ACE Guidelines for Glycemic Control. Endocrine Practice. 2003. 9 (1): 7-19.
27. Aldhahi W., Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr. Diab. Rep. 2003 Aug; 3 (4): 293-8.
28. Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome. J. Cardiovasc. Pharmacol. 1992; 20 (8): 29-31.
29. Aso Y., Wakabayashi S., Yamamoto R. et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care. 2005 Sep; 28 (9): 2211-6.
30. Barker D.J. Maternal nutrition, fetal nutrition, and disease in later life. Nutrition. 1997 Sep; 13 (9): 807-13.
31. Boucher B.J. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br. J. Nutr. 1998 Apr; 79 (4): 315-27.
32. Chiu K.C., Chu A., Go V.L. et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 2004 May; 79 (5): 820-5.
33. Dimova E.Y., Samoylenko A., Kietzmann T. Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression. Antioxid. Redox. Signal. 2004 Aug; 6 (4): 777-91.
34. Eckel Robert H. Obesity: mechanisms and clinical management. Philadelphia. LippincottWilliams and Wilkins. 2003; 378-398.
35. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NOEP) Expert Panel on detection, evaluation and Treatment of high blood Cholesterol in Adults (Adult Treatment Panel III) SAMA 2001; 285: 248-49.
36. Festa A., D'Agostino R. Jr., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002; 51: 1131-1137.
37. Guerrero-Romero F., Rodrigues-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol. 2002 Dec; 39 (4): 209-13.
38. Hoekstra T., Geleijnse J.M., Schouten E.G. et al. Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. Nutr. Metab. Cardiovasc Dis. 2005 Aug; 15 (4): 270-8.
39. Imperatore G., Riccardi G., Iovine C. et al. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care. 1998 Apr; 21 (4): 649-54.
40. Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 1989; 149: 1514-1520.
41. Reaven G., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympatoadrenal system. N. Engl. J. Med. 1996; 334: 374-381.
42. Shaw G.M., Velie E.M., Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA. 1996 Apr 10; 275 (14): 1127-8.
43. Skurk T., Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 2004 Nov; 28 (11): 1357-64.
44. Takaya J., Higashino H., Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes. Res. 2004 Jun; 17 (2): 126-36.
45. Werler M.M., Louik C., Shapiro S., Mitchell A.A. Prepregnant weight in relation to risk of neural tube defects. JAMA. 1996 Apr 10; 275 (14): 1127-8.
46.
47.
Review
For citations:
Perederyaeva E.B., Pshenichnikova T.B., Donina E.V., Makatsariya A.D., Kapanadze D.L. THE COURSE OF PREGNANCY IN WOMEN WITH METABOLIC SYNDROME IN VIEW OF PATHOGENETIC ROLE OF THROMBOPHILIA. Obstetrics, Gynecology and Reproduction. 2014;8(1):60-67. (In Russ.)
Views: 1213
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
